Mon, Sep 22, 2014, 5:05 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

clemcaldwell 1445 posts  |  Last Activity: Sep 20, 2014 2:36 PM Member since: Jul 7, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Enzalutamide, Abiraterone, and AR--V7

    by wilderguide Sep 19, 2014 2:26 PM
    clemcaldwell clemcaldwell Sep 20, 2014 2:36 PM Flag

    That along with the following and I'm sure other things will help with speed and cost savings.
    Mayo Clinic and designers of the IBM cognitive computer known as Watson will team up in 2015 to match the right patient to the right cancer-research study using a version of Watson specially designed for Mayo.
    We're in the middle of a data explosion like we've never seen before, Mike Rhodin, IBM Watson Group senior vice president, told more than 600 health care leaders at the Mayo Clinic Center for InnovationTransform symposium Monday.Watson is the cloud-computing system that famously won a specially arranged Jeopardy! competition.
    In an area like cancer — where time is of the essence — the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs, Mayo chair of medical oncology Dr. Steven Alberts said in a statement.IBM plans to feed into the Watson cloud-computing system all data available about current patient research studies at Mayo, and all clinical trials data from ClinicalTrials.gov.Watson will then match Mayo patients to the clinical trials most likely to benefit each individual patient, and it will give research teams the types of patients most needed for their individual studies.According to Mayo, the new Watson system is being trained to analyze patient records and clinical-trial criteria in order to determine appropriate matches for patients.

  • Reply to

    Enzalutamide, Abiraterone, and AR--V7

    by wilderguide Sep 19, 2014 2:26 PM
    clemcaldwell clemcaldwell Sep 19, 2014 3:53 PM Flag

    I was wondering because Ca. has so many raging. And aren't there a few near Redding?

  • Reply to

    Enzalutamide, Abiraterone, and AR--V7

    by wilderguide Sep 19, 2014 2:26 PM
    clemcaldwell clemcaldwell Sep 19, 2014 3:44 PM Flag

    Did you say you are involved in fighting forest fires?

  • clemcaldwell clemcaldwell Sep 19, 2014 3:33 PM Flag

    Abstracts chosen for the Presidential Symposium are so chosen for highest quality of presentation and notably successful application of cutting-edge technology.

  • clemcaldwell clemcaldwell Sep 18, 2014 5:35 PM Flag

    Presidential Symposium designation is for those that EMSO views as significant.It will include Roche's latest updates.So it is good to see the Phase 3 pivotal trial of cobimetinib in combination with vemurafenib in patients with previously untreated BRAF V600 mutation-positive advanced melanoma gets that. GSK and 1 or 2 other companies melanoma drugs are also getting the Presidential Symposium designation.If all goes well by the end of this year they will seek FDA approval.FDA approval could then come anytime from 6 months too 1 year from the submittal date.

  • clemcaldwell clemcaldwell Sep 17, 2014 3:47 PM Flag

    It refuses to post the rest of the article from FierceBiotech dated Sept.4,2014

  • Merck ($MRK) has won the frenzied race to secure the first FDA approval for a new breed of cancer treatment, clearing the way for a U.S. launch and a scramble for dominance in a field expected to peak at nearly $35 billion a year.The agency has signed off on Merck's pembrolizumab (formerly MK-3475) for melanoma, the first of the company's many planned indications. The drug is designed to galvanize an immune system attack on tumors by blocking a pathway called PD-1, which, left unchecked, allows cancerous cells to pass undetected. The approval, handed down almost two months ahead of schedule, clears the drug for use on patients with advanced skin cancers who have already taken Bristol-Myers Squibb's ($BMY) Yervoy (ipilimumab).With the victory, Merck becomes the first mover in a blockbuster race to commercialize a PD-1 treatment in the U.S., beating out rivals Bristol-Myers, AstraZeneca ($AZN) and Roche ($RHHBY), among others. Pembrolizumab, which will sell as Keytruda, is the second such therapy to win approval around the world, following last month's Japanese OK for nivolumab from Bristol-Myers and partner Ono Pharmaceutical.It won't be cheap. The cost for this drug will be $12,500 a month, or $150,000 a year, the low end of the ambitious range expected by Bernstein's Tim Anderson. That puts pembrolizumab on track to earn $3.5 billion a year, according to Anderson, which would make this treatment the first bona fide blockbuster to come out of Merck's pipeline in years. Nivolumab is still tapped by the analyst as the likely overall market winner, with $4.4 billion in expected peak sales. And Roche and AstraZeneca complete the top four group in immuno-oncology, with potential sales of $3.8 billion and $1.4 billion for their rival programs.The biggest promise for PD-1 blockers--both clinically and commercially--likely lies in combination therapies, and Merck has launched a fleet of cocktail studies that match pembrolizumab with treatments from Pfizer ($PFE), Amgen,

  • Abstracts accepted for presentation at ESMO 2014 as Poster Discussion and Poster will be published online on the ESMO website at 12:00 local Spanish time on Wednesday, 17 September 2014.
    Abstracts accepted for presentation at ESMO 2014 as Proffered Paper (oral presentation) will be published online on the ESMO website at 12:00 local Spanish time on Wednesday, 24 September 2014.
    Late-breaking abstracts will be made public at the beginning of the official Congress session during which they are presented.
    Abstracts selected for the official ESMO PR Programme will be made public at the end of the official Press Conference (9:00 local Spanish time) or at the beginning of the official Congress session during which they are presented, whichever comes first.

  • Reply to

    it would be great to see inside buys

    by mj525252 Sep 10, 2014 12:04 PM
    clemcaldwell clemcaldwell Sep 11, 2014 5:30 PM Flag

    Add Scott Garland to the list.

  • Reply to

    it would be great to see inside buys

    by mj525252 Sep 10, 2014 12:04 PM
    clemcaldwell clemcaldwell Sep 11, 2014 2:56 PM Flag

    The confidence in the outlook is shown by the top scientists who have not left.And the recent hiring of a lawyer, top scientist and investor relations people that came over from Gilead. And others from some respected and successful Biotechs.

  • Reply to

    it would be great to see inside buys

    by mj525252 Sep 10, 2014 12:04 PM
    clemcaldwell clemcaldwell Sep 10, 2014 3:33 PM Flag

    You hit the nail square on the head.I don't know why mj can't understand that after all these years and post similar to yours?MMM I believe has around 14 million shares, most in a blind trust.Why would he or anyone of the other top people at Exel buy shares when they have so many already in options,ESP plan,incentives etc..

  • Reply to

    IBM Mayo Clinic

    by clemcaldwell Sep 9, 2014 4:37 PM
    clemcaldwell clemcaldwell Sep 9, 2014 5:34 PM Flag

    If you like to remain ignorant of anything new about cancer be my guest.Also the Mayo Clinic Center for Innovation Transform Symposium held yesterday provided lots news.I tried to post the article but Yahoo wasn't working well enough to allow the post of interesting information.If all you can do is be detrimental to people get lost!

  • clemcaldwell by clemcaldwell Sep 9, 2014 4:37 PM Flag

    Mayo Clinic and designers of the IBM cognitive computer known as Watson will team up in 2015 to match the right patient to the right cancer-research study using a version of Watson specially designed for Mayo.
    We're in the middle of a data explosion like we've never seen before, Mike Rhodin, IBM Watson Group senior vice president, told more than 600 health care leaders at the Mayo Clinic Center for InnovationTransform symposium Monday.Watson is the cloud-computing system that famously won a specially arranged Jeopardy! competition.
    In an area like cancer — where time is of the essence — the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs, Mayo chair of medical oncology Dr. Steven Alberts said in a statement.IBM plans to feed into the Watson cloud-computing system all data available about current patient research studies at Mayo, and all clinical trials data from ClinicalTrials.gov.Watson will then match Mayo patients to the clinical trials most likely to benefit each individual patient, and it will give research teams the types of patients most needed for their individual studies.
    According to Mayo, the new Watson system is being trained to analyze patient records and clinical-trial criteria in order to determine appropriate matches for patients.

  • clemcaldwell clemcaldwell Sep 8, 2014 3:50 PM Flag

    Yahoo is not working well.I couldn't post the whole article.

  • clemcaldwell clemcaldwell Sep 8, 2014 3:29 PM Flag

    As has been said about Mayo Clinic many times, if you don't have margin, you don't have a mission, he said.
    Each year when he prepares to pick which health-insurance plan he wants, it's a quagmire for me — and I run the company,Bertolini said. His company, he said, is working on offering a set deductible for all policyholders and a $10 copayment, regardless of the procedure to simplify and make things less confusing for consumers.
    Had I not made it my job to manage my son's care, he would be dead today," Bertolini said.

  • Plenty of 0,000 to $100,000 or more for anotideas for changing U.S. health care were aired Sunday at the Mayo Clinic Center for Innovation Transform 2014 symposium, which continues today.
    They included more openness from providers about price and a focus on retail health care that makes it easier for patients to access care.
    Most strikingly, the traditional way of paying for health-care services is not designed to handle advances like genomics, nanotechnology and digital technology, said Dr. Mark McClellan, former director of the Food and Drug Administration and the Centers for Medicare and Medicaid Services.
    Such advances can extend life, but the initial cost is very expensive. But it's been shown that "people are wiling to spend $5her year of life," McClellan said.

  • Reply to

    The Comet Conundrum

    by wilderguide Sep 6, 2014 11:40 AM
    clemcaldwell clemcaldwell Sep 6, 2014 3:09 PM Flag

    From THE NEW PROSTATE CANCER INFOLINK
    There is little doubt that it is becoming a great deal harder to demonstrate a significant survival benefit in men with mCRPC who are treated with third-line therapy after docetaxel-based chemotherapy and after either abiraterone acetate or enzalutamide (or both). For new drugs to demonstrate real value in such patients, it seems highly likely that they are going to need to work in ways that are very different to those of available forms of treatment.

  • Reply to

    The Comet Conundrum

    by wilderguide Sep 6, 2014 11:40 AM
    clemcaldwell clemcaldwell Sep 6, 2014 2:50 PM Flag

    I'll say it again.You can not rely on the NCI site to be current.
    As the following example shows. This was sent to Apolo a couple of weeks ago.
    For the ClinicalTrials.gov Identifier:NCT0 1688999 it says:
    Cabozantinib; "It has not been approved for cancer treatment." Isn't
    that a mistake? It is approved for medullary thyroid cancer. The
    following is from the Exelixis homepage."COMETRIQ® (Kō-mĕ-trik)
    (cabozantinib) is a prescription medicine used to treat people with
    medullary thyroid cancer that has spread to other parts of the
    body."Shouldn't this mistake be corrected?
    The response was. When we started the trial it had not been approved yet. We can correct. Thanks. Apolo, Andrea (NIH/NCI)

  • Reply to

    RCC PFS Approvable Endpoint

    by duckduffer Sep 5, 2014 1:14 PM
    clemcaldwell clemcaldwell Sep 5, 2014 6:07 PM Flag

    Thanks.You are more intelligent than I.I appreciate the education.I 'm always ready for help in understanding these confounding trials.Ciao

EXEL
1.65-0.05(-2.94%)Sep 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.